Enoxaparin and Aspirin Compared with Aspirin Alone to Prevent Placenta-Mediated Pregnancy Complications

Obstetrics and Gynecology

Volumn 128, Issue 5, 2016, Pages 1053-1063

  Haddad, Bassam ^a   Winer, Norbert ^a   Chitrit, Yvon ^a   Houfflin Debarge, Véronique ^a   Chauleur, Céline ^a   Bages, Karine ^a   Tsatsaris, Vassilis ^a   Benachi, Alexandra ^a   Bretelle, Florence ^a   Gris, Jean Christophe ^a   Bastuji Garin, Sylvie ^a  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; ENOXAPARIN;

ADD ON THERAPY; ADULT; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GESTATIONAL AGE; HUMAN; INJECTION SITE PRURITUS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MATERNAL DEATH; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PERINATAL DEATH; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANT WOMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SMALL FOR DATE INFANT; SOLUTIO PLACENTAE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; PRE-ECLAMPSIA; PREGNANCY;

ABRUPTIO PLACENTAE; ADULT; ASPIRIN; DRUG THERAPY, COMBINATION; ENOXAPARIN; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY;

EID: 84992391305     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000001673     Document Type: Article

References (30)

1. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000;183:S1-S22
2. Caritis S, Sibai B, Hauth J, Lindheimer MD, Klebanoff M, Thom E, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. N Engl J Med 1998;338:701-5
3. Hnat MD, Sibai BM, Caritis S, Hauth J, Lindheimer MD, MacPherson C, et al. Perinatal outcome in women with recurrent preeclampsia compared with women who develop preeclampsia as nulliparous. Am J Obstet Gynecol 2002;186:422-6
4. Sibai BM. Chronic hypertension in pregnancy. Obstet Gynecol 2002;100:369-77
5. Sibai BM, Hauth J, Caritis S, Lindheimer MD, MacPherson C, Klebanoff M, et al. Hypertensive disorders in twin versus singleton gestations. Am J Obstet Gynecol 2000;182:938-42
6. Haddad B, Deis S, Goffinet F, Paniel BJ, Cabrol D, Sibai BM. Maternal and perinatal outcomes during expectant management of 239 severe preeclamptic women between 24 and 33 weeks' gestation. Am J Obstet Gynecol 2004;190:1590-5
7. Sibai BM, el-Nazer A, Gonzalez-Ruiz A. Severe preeclampsiaeclampsia in young primigravid women: subsequent pregnancy outcome and remote prognosis. Am J Obstet Gynecol 1986; 155:1011-6
8. van Rijn BB, Hoeks LB, Bots ML, Franx A, Bruinse HW. Outcomes of subsequent pregnancy after first pregnancy with earlyonset preeclampsia. Am J Obstet Gynecol 2006;195:723-8
9. Bramham K, Briley AL, Seed P, Poston L, Shennan AH, Chappell LC. Adverse maternal and perinatal outcomes in women with previous preeclampsia: a prospective study. Am J Obstet Gynecol 2011;204:512.e1-9
10. Langenveld J, Buttinger A, van der Post J, Wolf H, Mol BW, Ganzevoort W. Recurrence risk and prediction of a delivery under 34 weeks of gestation after a history of a severe hypertensive disorder. BJOG 2011;118:589-95
11. Rodger MA, Carrier M, Le Gal G, Martinelli I, Perna A, Rey E, et al. Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. Blood 2014;123:822-8
12. Rodger MA, Hague WM, Kingdom J, Kahn SR, Karovitch A, Sermer M, et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet 2014;384:1673-83
13. Mamelle N, Boniol M, Rivière O, Joly MO, Mellier G, Maria B, et al. Identification of newborns with Fetal Growth Restriction (FGR) in weight and/or length based on constitutional growth potential. Eur J Pediatr 2006;165:717-25
14. Kahan BC, Morris TP. Assessing potential sources of clustering in individually randomized trials. BMC Med Res Methodol 2013;13:58
15. Executive summary: hypertension in Pregnancy. Hypertension in pregnancy. American College of Obstetricians and Gynecologists. Obstet Gynecol 2013;122:1122-31
16. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med 2010;7:e1000251
17. Staff AC, Johnsen GM, Dechend R, Redman CW. Preeclampsia and uteroplacental acute atherosis: immune and inflammatory factors. J Reprod Immunol 2014;101-102:120-6
18. McLaughlin K, Drewlo S, Parker JD, Kingdom JCP. Current theories on the prevention of severe preeclampsia with lowmolecular weight heparin. Hypertension 2015;66:1098-103
19. Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis JS. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 2000; 83:693-7
20. Grandone E, Brancaccio V, Colaizzo D, Sciannamé N, Pavone G, Di Minno G, et al. Preventing adverse obstetric outcomes in women with genetic thrombophilia. Fertil Steril 2002; 78:371-5
21. Kupferminc MJ, Fait G, Many A, Lessing JB, Yair D, Bar-Am A, et al. Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias. Hypertens Pregnancy 2001;20:35-44
22. Gris JC, Chauleur C, Molinari N, Marès P, Fabbro-Peray P, Quéré I, et al. Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial. Thromb Haemost 2011;106: 1053-61
23. Mello G, Parretti E, Fatini C, Riviello C, Gensini F, Marchionni M, et al. Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension 2005;45:86-91
24. Rey E, Garneau P, David M, Gauthier R, Leduc L, Michon N, et al. Dalteparin for the prevention of recurrence of placentalmediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost 2009;7:58-64
25. Gris JC, Chauleur C, Faillie JL, Baer G, Marès P, Fabbro-Peray P, et al. Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae. The pilot randomised controlled NOH-AP trial. Thromb Haemost 2010;104:771-79
26. Martinelli I, Ruggenenti P, Cetin I, Pardi G, Perna A, Vergani P, et al, and the HAPPY Study Group. Heparin in pregnant women with previous placenta mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood 2012;119:3269-75
27. deVries JIP, van Pampus MG, Hague WM, Bezemer PD, Joosten JH, and the FRUIT Investigators. Low-molecularweight heparin added to aspirin in the prevention ofrecurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. J Thromb Haemost 2012;10:64-72
28. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2010;116:402-14
29. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005;106:401-7
30. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692-4